|
|
|
|
|
Prazosin
drug data and news
Prazosin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Prazosin | ||
| Brand Names/Synonyms | CHEMBANK349; Furazosin; HSDB 3298; Lentopres; Minipress; Minipress Xl; Prazosin; Prazosin Base; Prazosin Hcl; Prazosin Hydrochloride; Prazosina [Inn-Spanish]; Prazosine [Inn-French]; Prazosinum [Inn-Latin]; Vasoflex | ||
| Indication | For treatment of hypertension and chronic heart failure. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Prazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Prazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Prazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Prazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Prazosin results from a decrease in systemic vascular resistance and the parent compound Prazosin is primarily responsible for the antihypertensive activity. | ||
| Mechanism Of Action | Prazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. | ||
| Prazosin News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antihypertensive Agents; Alpha-adrenergic Blocking Agents; ATC:C02CA01 | ||
| Absorption | Well-absorbed from gastrointestinal tract; bioavailability is variable (50 to 85%). | ||
| Interactions |
Interactions for Prazosin: Prazosin has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides - digitalis and digoxin; (2) hypoglycemics - insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives - chlordiazepoxide, diazepam, and phenobarbital; (4) antigout - allopurinol, colchicine, and probenecid; (5) antiarrhythmics - procainamide, propranolol , and quinidine; and (6) analgesics, antipyretics and anti-inflammatories - propoxyphene, aspirin, indomethacin, and phenylbutazone. Addition of a diuretic or other antihypertensive agent to prazosin HCl has been shown to cause an additive hypotensive effect. This effect can be minimized by reducing the prazosin dose to 1 to 2mg three times a day, by introducing additional antihypertensive drugs cautiously and then by retitrating prazosin based on clinical response. Drug/Laboratory Test Interactions In a study on five patients given from 12 to 24 mg of prazosin per day for 10 to 14 days, there was an average increase of 42% in the urinary metabolite of norepinephrine and an average increase in urinary VMA of 17%. Therefore, false positive results may occur in screening tests for pheochromocytoma in patients who are being treated with prazosin. If an elevated VMA is found, prazosin should be discontinued and the patient retested after a month. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone | ||
| Chemical Formula | C19H21N5O4 | ||
| Molecular Weight | 383.401 g/mol | ||
| Smiles String | COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC | ||
| Melting Point | 279 °C | ||
| Water Solubility | 0.2 mg/mL (as HCl salt) | ||
| State | Solid | ||
| LogP/Hphobicity | 0.934 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Primarily hepatic. Several metabolites have been identified in humans and animals (6- O -demethyl, 7- O -demethyl, 2-[1-piperazinyl]-4-amino-6, 7-dimethoxyquinazoline, 2,4-diamino-6,7-dimethoxyquinazoline). | ||
| Half Life | 2-3 hours | ||
| Protein Binding [%] | 97% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Prazosin.html http://www.rxlist.com/cgi/generic3/prazosin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00020 | ||
| CAS Registry Number | 19216-56-9 | ||
| KEGG Compound ID | C07368 | ||
| PubChem ID | SID:9572 | ||
| PharmGKB ID | PA451093 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 1910302 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |